Disclosed is the use of: i) one or more antigens and ii) an adjuvant, said adjuvant comprising one or more carboxylic acids and optionally one or more mono-glycerides in the manufacture of a vaccine composition for avoiding Bell’s palsy in a frequency higher than the naturally occurring incidence, following vaccination in a human.